Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer, August 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 114 articles: HTML format

Single Articles

1. OGUNKEYE J, Shkolyar E, Mach KE, Prendiville S, et al
   Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection.
   Eur Urol Focus. 2026 Jul 31:S2405-4569(26)00097.
   PubMed    
   Abstract available
   
   

2. USUI K, Ito H, Muraoka K, Noto N, et al
   Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Variant Histology Bladder Cancer: A Multi-institutional Propensity Score-Matched Analysis.
   Clin Genitourin Cancer. 2026;24:102618.
   PubMed    
   Abstract available
   
   

3. GAO S, Jiang P, Liu X, Wang J, et al
   Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer.
   Biosens Bioelectron. 2026;312:119076.
   PubMed    
   Abstract available
   
   

4. BOGALE DE
   Activation of the PI3K/AKT/mTOR signaling pathway in bladder cancer pathogenesis and its therapeutic significance.
   Cancer Treat Res Commun. 2026;48:101340.
   PubMed    
   Abstract available
   
   

5. ABDULLAH OR, Short K, Alomari LHF, Ignatowicz A, et al
   Venous thromboembolism in urothelial bladder cancer - scope of the problem and patients' perspectives: VTE-UBC.
   Wiad Lek. 2026;79:1169-1178.
   PubMed    
   Abstract available
   
   

6. ZHONG C, Masters M, Donzella SM, Bliwise DL, et al
   Risk of bladder cancer among male participants reporting nocturia in the Cancer Prevention Study-II.
   Cancer Epidemiol Biomarkers Prev. 2026.
   PubMed    
   Abstract available
   
   

7. NIEGISCH G, Grunewald C
   [Perioperative treatment of muscle-invasive bladder cancer : Current treatment concepts].
   Urologie. 2026 Jul 31. doi: 10.1007/s00120-026-02900.
   PubMed    
   Abstract available
   
   

8. MO Z, Gai S, Qin X, Meng D, et al
   Retraction notice to "Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein" [Int. J. Biol. Macromol. 301 (2025) 140438].
   Int J Biol Macromol. 2026 Jul 30:153654. doi: 10.1016/j.ijbiomac.2026.153654.
   PubMed    
   
   
   

9. VERMA GK, Saini D, Chaudhary PK, Saha S, et al
   Association between heavy metal exposure and epigenetic modifications in patients with urinary bladder cancer.
   Gene. 2026 Jul 30:150330. doi: 10.1016/j.gene.2026.150330.
   PubMed    
   Abstract available
   
   

10. CHEVILLE JC, Tekin B, Orme JJ, Jimenez RE, et al
    ERBB2 Copy Number Alterations and Protein Expression in Bladder Cancer Treated by Cystectomy.
    Hum Pathol. 2026 Jul 30:106217. doi: 10.1016/j.humpath.2026.106217.
    PubMed    
    Abstract available
    
    

11. HENDRI AZ, Robert R, Febriyanto T, Liliana B, et al
    Prognostic significance of TOP2A expression in bladder cancer: Systematic review and meta-analysis.
    Can Urol Assoc J. 2026 Jul 20. doi: 10.5489/cuaj.9572.
    PubMed    
    Abstract available
    
    

12. SAYED U, Basheer NM, H M, Nayak PP, et al
    Kinesins in Bladder Cancer: Integrating Molecular Mechanisms and Treatment Approaches.
    Cell Biol Int. 2026;50:e70191.
    PubMed    
    Abstract available
    
    

13. JIN J, Jin Y, Zhang R, Li Y, et al
    A novel quinoline and manganese-based carbon monoxide-releasing molecule for intravesical therapy of bladder cancer.
    Br J Pharmacol. 2026 Jul 30. doi: 10.1111/bph.70614.
    PubMed    
    Abstract available
    
    

14. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
    Comparison of 5-aminolevulinic acid-induced hypotension of extending the oral administration period during photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2026 Jul 29:105591.
    PubMed    
    Abstract available
    
    

15. GU T, Gunelli R, Chen T, Wang C, et al
    Robotic-assisted intracorporeal radical cystectomy with modified ileal conduit reduces ureteroileal anastomotic stenosis risk: a comparative study with laparoscopic surgery.
    Ann Med. 2026;58:2703361.
    PubMed    
    Abstract available
    
    

16. GAN L, Wu J, Li Z, Cao H, et al
    Intra-corporeal robot-assisted versus open radical cystectomy: a meta-analysis.
    World J Urol. 2026;44:531.
    PubMed    
    Abstract available
    
    

17. SALAH IBRAHIM A, Gamal DA, Hadia A, Hasaballah A, et al
    Superiority of Adjuvant Hyperfractionated Radiotherapy Over Chemotherapy Following Radical Cystectomy.
    Asian Pac J Cancer Prev. 2026;27:2571-2580.
    PubMed    
    Abstract available
    
    

18. DA SILVA IM, Rocha LMO, de Andrade QG, de Lima LVA, et al
    Telomere stability pathway genes as predictors of susceptibility and prognosis in urothelial bladder cancer: review and bioinformatics analyses.
    J Toxicol Environ Health B Crit Rev. 2026.
    PubMed    
    Abstract available
    
    

19. ANTONELLI L, Afferi L, Del Giudice F, Bologna E, et al
    Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2026 Jul 28:S2405-4569(26)00155.
    PubMed    
    Abstract available
    
    

20. SUARTZ CV, Huber IMT, Brito PHS, de Lima RD, et al
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Neoadjuvant and Adjuvant Strategies.
    Clin Oncol (R Coll Radiol). 2026;57:104281.
    PubMed    
    Abstract available
    
    

21. DE MIGUEL-GARCIA G, Ruiz de Porras V, Font-Moron M, Font A, et al
    Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification.
    Biomed Pharmacother. 2026;202:119807.
    PubMed    
    Abstract available
    
    

22. WANG B, Zou J, Gao L, Lou F, et al
    Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study.
    Asia Pac J Oncol Nurs. 2026;13:101001.
    PubMed    
    Abstract available
    
    

23. LAINEZ N, Martinez-Kareaga M, Sagastibeltza-Marinalarena N, Sanchez M, et al
    Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.
    ESMO Real World Data Digit Oncol. 2026;13:100732.
    PubMed    
    Abstract available
    
    

24. XU J, Xiong Y, Liu C, Sun J, et al
    Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.
    Mol Biomed. 2026;7:119.
    PubMed    
    Abstract available
    
    

25. HAGE L, Chakra MA, O'Donnell MA, Userovici M, et al
    Clinical patterns and pathogenesis of bladder leiomyoma: a multicenter observational study.
    World J Urol. 2026;44:526.
    PubMed    
    Abstract available
    
    

26. TANAKA T, Oriyama T, Yamamoto T, Kimura S, et al
    Risk factors for chemotherapy-induced dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy: a retrospective observational study.
    Support Care Cancer. 2026;34:808.
    PubMed    
    Abstract available
    
    

27. LUO Y, Liu X, Zhu S, Lin P, et al
    Clonal evolution and stromal crosstalk drive an invasive epithelial program in bladder cancer.
    Front Cell Dev Biol. 2026;14:1809774.
    PubMed    
    Abstract available
    
    

28. LIU T, Li W, Yin Q, Liu D, et al
    Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.
    Pharmaceuticals (Basel). 2026;19:1116.
    PubMed    
    Abstract available
    
    

29. CANCERS EDITORIAL OFFICE
    Expression of Concern: Park et al. Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers 2019, 11, 1494.
    Cancers (Basel). 2026;18:2357.
    PubMed    
    Abstract available
    
    

30. SALA-GONZALEZ N, Chekhun S, Fina C, Vilaseca M, et al
    Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review.
    Cancers (Basel). 2026;18:2269.
    PubMed    
    Abstract available
    
    

31. MUKHERJEE N, Ji N, Hassouneh Z, Furman J, et al
    Unveiling the Paradoxical Tumor-Suppressive Role of CCL2/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy.
    Cancers (Basel). 2026;18:2267.
    PubMed    
    Abstract available
    
    

32. PEREZ M, Lozano JJ, Ingelmo-Torres M, Domenech M, et al
    Correction: Perez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.
    Biomedicines. 2026;14:1604.
    PubMed    
    Abstract available
    
    

33. GIMALOVA G, Gilyazova I, Khusnutdinova E, Pavlov V, et al
    SnoRNA and SNHG in Bladder Cancer: Molecular Mechanisms and Clinical Significance.
    Curr Issues Mol Biol. 2026;48:662.
    PubMed    
    Abstract available
    
    

34. UGUR R, Demiriz B, Nisli O, Keskin ET, et al
    Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non-Muscle-Invasive Bladder Cancer?
    Ann Surg Oncol. 2026 Jul 27. doi: 10.1245/s10434-026-20268.
    PubMed    
    Abstract available
    
    

35. TYSON MD 2ND, Nam JK, Joshi SS, Uchio EM, et al
    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
    Lancet Oncol. 2026;27:983-993.
    PubMed    
    Abstract available
    
    

36. AKPINAR C, Aydog E, Sahin B, Gulsen M, et al
    Contemporary Trends in the Surgical and Systemic Management of Muscle-Invasive Bladder Cancer: Insights From a Nationwide Multicenter Cohort in Turkey Over 2 Decades.
    Clin Genitourin Cancer. 2026;24:102612.
    PubMed    
    Abstract available
    
    

37. ALI M, Soliman SE, Eldeeb TS, Aboeleuon E, et al
    Muscle invasion in bladder cancer is associated with increased expression of ATG5, LC3A and CHOP.
    Mol Biol Rep. 2026;53:1281.
    PubMed    
    Abstract available
    
    

38. BEDKE J, Eccleston A, Unsworth M, Brinkmann J, et al
    Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.
    Future Oncol. 2026 Jul 27:1-14. doi: 10.1080/14796694.2026.2696928.
    PubMed    
    Abstract available
    
    

39. WANG W, Li D, Liu J, Li L, et al
    Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors.
    J Med Chem. 2026 Jul 27. doi: 10.1021/acs.jmedchem.6c01714.
    PubMed    
    Abstract available
    
    

40. ZHANG Y, Shi X, Yuan Y, Gao X, et al
    MoN/Au/cTAT Boosted Sonochemotherapy Post-Intravesical Instillation in Bladder Cancer.
    Small. 2026 Jul 27:e11210. doi: 10.1002/smll.202511210.
    PubMed    
    Abstract available
    
    

41. FREY LJ, Lache N, Fischer ND, Rolz N, et al
    Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.
    Oncol Res. 2026;34:14.
    PubMed    
    Abstract available
    
    

42. WANG YD, Lai YL, Liu CH, Su YT, et al
    Epigenomics-Guided Multi-Omics Integration Uncovers a Lipid-Metabolic Signature with Translational Utility in Bladder Cancer.
    Comput Struct Biotechnol J. 2026;35:0139.
    PubMed    
    Abstract available
    
    

43. ISHIGAMI Y, Takahashi M, Nakatsukasa H, Shibano M, et al
    Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.
    Immunotherapy. 2026;18.
    PubMed    
    Abstract available
    
    

44. TYAGI B, Tyagi A, Vashishta M, Tyagi N, et al
    Integrated analyses of the microbiome, metabolome, and spatial transcriptomics reveal sex-dependent bladder vulnerability to chronic inorganic arsenic.
    J Hazard Mater. 2026;514:142653.
    PubMed    
    Abstract available
    
    

45. CAO S, Chen Z, Wang S, Zhou Q, et al
    Arsenic induced deubiquitination modification of PLCE1 in a de-SUMO-dependent manner to affect malignant behavior in bladder epithelial cells.
    J Hazard Mater. 2026;514:142786.
    PubMed    
    Abstract available
    
    

46. ZHU A, Singh Z, Holt SK, Schade GR, et al
    Impact of low levels of arsenic in drinking water with incident urologic cancers in Washington state.
    J Hazard Mater. 2026;514:142671.
    PubMed    
    Abstract available
    
    

47. ZHU Y, Hu Q, Zhang R, Zhang G, et al
    Advancements in Endoscopic Optical Coherence Tomography for Urothelial Carcinoma: Research Progress and Clinical Applications.
    Curr Med Imaging. 2026;22:e15734056434411.
    PubMed    
    Abstract available
    
    

48. DIANA P, Paciotti M, Frego N, Gallioli A, et al
    Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics.
    Eur Urol Focus. 2026;12:377-382.
    PubMed    
    Abstract available
    
    

49. TILKI B, Guler OC, Demirhan B, Hurmuz P, et al
    Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience.
    Clin Transl Radiat Oncol. 2026;60:101246.
    PubMed    
    Abstract available
    
    

50. ELEFTHERIOU C, Zhao Y, Lami M, Boaz RJ, et al
    Comparison of postoperative and early oncological outcomes of open versus robotic radical cystectomy.
    J Robot Surg. 2026;20:808.
    PubMed    
    Abstract available
    
    

51. DOLEK EK, Biyikoglu M, Cayan S, Senel S, et al
    The Effect of Intravesical Bacillus Calmette-Guerin Treatment on Sexual Functions and Mental Health in Male and Female Patients Diagnosed with Non-Muscle Invasive Bladder Cancer.
    Urol Res Pract. 2026;52:1-8.
    PubMed    
    Abstract available
    
    

52. XU J, Huang Y, Ni G, Huang Y, et al
    Hemostatic Efficacy and Clinical Outcomes of Radiotherapy in Older Adult Patients With Advanced Bladder Cancer and Hematuria Unsuitable for Standard Treatment.
    Med Sci Monit. 2026;32:e953113.
    PubMed    
    Abstract available
    
    

53. DEZA I, de Lacy Costello B, Drabinska-Fois N, White P, et al
    Urinary volatilomics using liquid-liquid extraction and gas chromatography-mass spectrometry (GC-MS) combined with machine learning algorithms as a tool for diagnosis and surveillance of urothelial bladder cancer.
    BJC Rep. 2026;4:42.
    PubMed    
    Abstract available
    
    

54. SFORZA S, Lubbersmeyer F, Mari A
    Prognostic Factors After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: From Prognostication to Patient Selection.
    Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00200-2. doi: 10.1016/j.euo.2026.
    PubMed    
    
    
    

55. ST-LAURENT MP, Eigl BJ, Tyldesley S, Yuan R, et al
    NeoBLAST: A Pilot Randomized Controlled Trial of Active Surveillance Versus Definitive Bladder Treatment Following Clinical Complete Response to Neoadjuvant Therapy in Muscle-invasive Bladder Cancer - Study Protocol.
    Eur Urol Oncol. 2026 Aug 7:S2588-9311(26)00198-7. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available
    
    

56. YANG X, Cai L, Wang C, Tan Z, et al
    The Prognostic Role of HER2 Expression in Patients With Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026;24:102624.
    PubMed    
    Abstract available
    
    

57. XU Z, Wang X
    Intracorporeal urinary diversion during robot-assisted radical cystectomy: a bibliometric and visualization analysis of research evolution, evidence landscape, learning curves, and clinical outcomes.
    J Robot Surg. 2026;20:806.
    PubMed    
    Abstract available
    
    

58. IKEHATA Y, Nishiyama N, Miyake M, Nishimura N, et al
    Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guerin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group).
    Jpn J Clin Oncol. 2026 Aug 7:hyag124. doi: 10.1093.
    PubMed    
    Abstract available
    
    

59. TYSON MD 2ND, Choudry MM, McKee C, Kalaria S, et al
    Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population.
    JU Open Plus. 2026;4:e00085.
    PubMed    
    Abstract available
    
    

60. DONG X, Chen Z, Chen Y, Xiao Z, et al
    Mechanical stress, metabolic reprogramming and stromal remodeling: an emerging paradigm in the bladder cancer mechano-micro-environment.
    Front Genet. 2026;17:1896399.
    PubMed    
    Abstract available
    
    

61. GOH NS
    Presumed Simultaneous Intraocular and Extraocular BCG-osis as a Complication of Intravesical Bacillus Calmette-Guerin Treatment for Non-Muscle-Invasive Bladder Cancer: A Case Report.
    Cureus. 2026;18:e114020.
    PubMed    
    Abstract available
    
    

62. DIAO X, Che B, Zhai J, Shao B, et al
    Decoding the temporal dimension of innate immunity in intravesical BCG therapy.
    Front Immunol. 2026;17:1904049.
    PubMed    
    Abstract available
    
    

63. SAAD A, Daraan FM, Barghouth I, Sleiay M, et al
    Complete Response to Intravesical BCG for High-Risk pT1 Bladder Cancer With Lymphovascular Invasion: A Case Report.
    Case Rep Oncol Med. 2026;2026:7517129.
    PubMed    
    Abstract available
    
    

64. HENSLEY PJ, Teoh JYC, Li R, Gupta S, et al
    Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.
    Nat Rev Urol. 2026 Aug 5. doi: 10.1038/s41585-026-01179.
    PubMed    
    Abstract available
    
    

65. SAAD MA, Antari A, Taleb I, El Omri S, et al
    Bacillus Calmette-Guerin (BCG) with or without immune checkpoint blockade in BCG-naive high-risk non-muscle-invasive bladder cancer: A systematic review and reconstructed individual patient data meta-analysis.
    Crit Rev Oncol Hematol. 2026;227:105510.
    PubMed    
    Abstract available
    
    

66. KIEBACH J, Kamps CSAD, Wesselink E, Aben KKH, et al
    Lifestyle and dietary inflammation scores and risks of recurrence and progression among patients with non-muscle invasive bladder cancer.
    Nutrition. 2026;151:113354.
    PubMed    
    Abstract available
    
    

67. ZUO J, Tan Y, Mu Z, Dong Y, et al
    Assembly-formed bioorthogonal chimeric artificial receptors enable high-contrast fluorescence imaging of tumors.
    Sci Adv. 2026;12:eaed9403.
    PubMed    
    Abstract available
    
    

68. GAOL LML, Prabaningrum YSK, Andy, Swity AF, et al
    Atypical desmoplastic small round cell tumor (DSRCT) mimicking muscle-invasive bladder cancer (MIBC) in a child: Surgical approach using ileal diversion.
    Radiol Case Rep. 2026;21:4398-4404.
    PubMed    
    Abstract available
    
    

69. ZHOU L, Zhu J, Liu Y, Xu B, et al
    Integrated Immunological Analysis of Interactions Between CXCL13+ T Cells and LAMP3+ DC in the Immunotherapy Response of Bladder Cancer.
    Mol Carcinog. 2026 Aug 5. doi: 10.1002/mc.70162.
    PubMed    
    Abstract available
    
    

70. CHEN Y, Jiang Y, Yang Z, Jing M, et al
    LAMC2(+) Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis.
    Cancer Sci. 2026 Aug 5:10.1111/cas.70492. doi: 10.1111/cas.70492.
    PubMed    
    Abstract available
    
    

71. AYDIN A, Abdulmajeed AS, Bekiroglu FB, Kocak M, et al
    Investigating gender disparities in urological care for non-muscle invasive bladder cancer (NMIBC).
    BJUI Compass. 2026;7:e70245.
    PubMed    
    Abstract available
    
    

72. AYDOGDU C, Wang B, McSweeney S, Pieretti A, et al
    ASO Visual Abstract: Preoperative Tumor-Informed ctDNA for Prediction of Nodal Metastases at Radical Cystectomy in Bladder Cancer.
    Ann Surg Oncol. 2026 Aug 4. doi: 10.1245/s10434-026-20121.
    PubMed    
    
    
    

73. HORI J, Tokumitsu M, Yamaguchi S, Ishida H, et al
    [Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital].
    Gan To Kagaku Ryoho. 2026;53:407-412.
    PubMed    
    Abstract available
    
    

74. ZHANG S, Li M, Wu Y, Kang Y, et al
    Circ_0001495 promotes bladder cancer progression by regulating miR-1184 via MAPK signaling pathway.
    Mol Biol Rep. 2026;53:1337.
    PubMed    
    Abstract available
    
    

75. TANAKA N, Miyajima A, Kosaka T, Shirotake S, et al
    Editor's Note: Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer.
    Mol Cancer Ther. 2026;25:1410.
    PubMed    
    
    
    

76. SCILIPOTI P, Rosiello G, Salonia A, Briganti A, et al
    Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery.
    Nat Rev Urol. 2026 Aug 3. doi: 10.1038/s41585-026-01180.
    PubMed    
    
    
    

77. MALMSTROM PU, Dragomir A, Gardmark T
    Validation of an AI-based Histologic Prognostic Biomarker in Patients with Non-muscle-invasive Bladder Cancer Using the Prospective Swedish National Register of Urinary Bladder Cancer.
    Eur Urol Oncol. 2026 Aug 4:S2588-9311(26)00192-6. doi: 10.1016/j.euo.2026.
    PubMed    
    
    
    

78. AGHAMIR SMK, Rahimnia R, Taheri D, Ebrahimi M, et al
    Prognostic value of different biomarkers in bladder cancer: protocol for an umbrella review of systematic reviews and meta-analyses.
    BMJ Open. 2026;16:e118810.
    PubMed    
    Abstract available
    
    

79. HAWEZ L, Bergengren O, Ahlberg M, Garmo H, et al
    Suicide risk among urinary bladder cancer patients compared with the standard population: a nationwide study in Sweden.
    Scand J Urol. 2025;60:204-208.
    PubMed    
    Abstract available
    
    

80. MORENO-VEGA A, Zambrano M, Estrada-Virrueta L, Meng X, et al
    FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.
    J Clin Invest. 2026;136:e193280.
    PubMed    
    Abstract available
    
    

81. UGUR R, Demiriz B, Nisli O, Keskin ET, et al
    ASO Visual Abstract: Who is at Risk of Residual Tumor and Pathologic Upstaging at Second TURBT in Non-Muscle-Invasive Bladder Cancer?
    Ann Surg Oncol. 2026 Aug 1. doi: 10.1245/s10434-026-20351.
    PubMed    
    
    
    

82. ZENG Z, Hu C, Li Y, Ding B, et al
    Smart nanoplatform targeting the mitochondria-P-gp axis to overcome chemoresistance for synergistic bladder cancer therapy.
    Colloids Surf B Biointerfaces. 2026;268.
    PubMed    
    Abstract available
    
    

83. RUTTEN VC, van Rijen NMA, Franckena M, Robbrecht DGJ, et al
    Real-world Impact of Integrating Comprehensive Geriatric Assessment into Clinical Treatment Decision-making for Older Patients with Bladder Cancer.
    Eur Urol Open Sci. 2026;91:23-31.
    PubMed    
    Abstract available
    
    

84. FUKUHARA H, Shimasaki S, Yamashita E, Kurano Y, et al
    Transurethral laser ablation using 980-nm diode laser for recurrent non-muscle invasive bladder cancer.
    Explor Target Antitumor Ther. 2026;7:1002386.
    PubMed    
    Abstract available
    
    

85. MUSCATELLO LV, Bacci B, Brigandi E, Tugnoli C, et al
    Computer-aided image analysis for PD-L1 assessment in canine urothelial carcinoma.
    Vet J. 2026;318:106758.
    PubMed    
    Abstract available
    
    

86. EINERHAND SMH, Ali H, Wong SQ, van Dorp J, et al
    Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.
    Nat Commun. 2026;17:7679.
    PubMed    
    Abstract available
    
    

87. SUARTZ CV, Azevedo MFD, Brito PHS, Setoue DND, et al
    Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center.
    BMC Urol. 2026;26:189.
    PubMed    
    Abstract available
    
    

88. YEH CC, Fan CS, Chen LL, Chua KV, et al
    Preclinical evaluation of rBCG-h12: an engineered Bacillus Calmette-Guerin with an enhanced activity against bladder and pancreatic cancers.
    Cancer Immunol Immunother. 2026;75:202.
    PubMed    
    Abstract available
    
    

89. WOO S, Muglia VF, Luk L, Takeuchi M, et al
    What's next for VI-RADS? Updates and future perspectives from the ACR VI-RADS steering committee.
    Cancer Imaging. 2026;26:97.
    PubMed    
    Abstract available
    
    

90. THAI KL, Le PND, Nguyen TT, Ngo XT, et al
    Clinical and imaging predictors of urachal carcinoma: the role of gross hematuria and calcification in a single-center retrospective study.
    BMC Urol. 2026;26:190.
    PubMed    
    Abstract available
    
    

91. MATSUBARA N, Saijo K, Shimizu Y, Okano S, et al
    First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.
    Cancer Sci. 2026;117:2247-2258.
    PubMed    
    Abstract available
    
    

92. VARANASI P, Wengenack N, Steidley DE, Kodali L, et al
    Disseminated Mycobacterium bovis-BCG Infection Following Intravesical BCG Administration in Solid Organ Transplant Recipients.
    Transpl Infect Dis. 2026;28:e70220.
    PubMed    
    Abstract available
    
    

93. TEH A, Sima T, Shinozaki E, Malik R, et al
    A case of canine urothelial carcinoma of the urinary bladder with skull and skeletal metastases.
    Aust Vet J. 2026;104:509-514.
    PubMed    
    Abstract available
    
    

94. LEE T, Akgul M, Fernandez-Pol S, Aron M, et al
    Immunohistochemical Expression of p63 and GATA3 in Lymphomas of the Urinary Bladder: A Clinicopathologic Study of a Potential Diagnostic Pitfall.
    Int J Surg Pathol. 2026;34:1483-1488.
    PubMed    
    Abstract available
    
    

95. MITRA S, Shangloo A, Bhatkule MA, Akif S, et al
    Complete Colonic Metaplasia of the Urinary Bladder and Ureters With Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder: A Rare Occurrence.
    Int J Surg Pathol. 2026;34:1630-1635.
    PubMed    
    Abstract available
    
    

96. BUDINA A, Vergara N, Navarro FE, Morrissette JJD, et al
    High-Grade Urothelial Carcinoma with Divergent Prostatic Differentiation Mimicking a Collision Tumor in a Bladder Diverticulum.
    Int J Surg Pathol. 2026;34:1570-1578.
    PubMed    
    Abstract available
    
    

97. GRYPARI IM, Pomoni A, Ganetsou D, Kouroukli O, et al
    True Papillae and Squamous Features in Prostate Carcinoma Represent a Potential Diagnostic Pitfall: Report of 3 Patients.
    Int J Surg Pathol. 2026;34:1610-1615.
    PubMed    
    Abstract available
    
    

98. POLAT UNAL SE, Suren D, Kurtoglu E
    Primary Classical Hodgkin Lymphoma of the Urinary Bladder: Expanding the Spectrum of Bladder Lymphoid Neoplasms.
    Int J Surg Pathol. 2026;34:1586-1590.
    PubMed    
    Abstract available
    
    

99. ILMIAH K, Parengkuan IL, Rahaju AS, Mastutik G, et al
    Bladder Urothelial Neoplasms Profile in Dr. Soetomo General Academic Hospital Surabaya: Retrospective Study during 2013-2023.
    Urologia. 2026;93:384-388.
    PubMed    
    Abstract available
    
    

100. ILKTAC A, Dogan B, Gevher F, Akcay M, et al
     Hematuria-related readmission after transurethral resection of bladder tumor in patients receiving antiplatelet therapy.
     Urologia. 2026;93:370-375.
     PubMed    
     Abstract available
     
     

101. JAVID RAJA IYUB M, Prabhakar P, Pon Avudaiappan A, Sakthivel DK, et al
     Postoperative ileus following radical cystectomy in current urological practice: Incidence and risk factors.
     Urologia. 2026;93:376-383.
     PubMed    
     Abstract available
     
     

102. KITAHAMA K, Inamura K
     Inverted urothelial papilloma: Diagnostic challenges, molecular insights, and clinical implications.
     Histol Histopathol. 2026;41:1483-1491.
     PubMed    
     Abstract available
     
     

103. AL ARMASHI AR, Gong J, Barata P, Brown J, et al
     Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing.
     Expert Rev Anticancer Ther. 2026;26:1003-1017.
     PubMed    
     Abstract available
     
     

104. KOBARI Y, Nakajima N, Saito A, Katsurayama N, et al
     Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
     Anticancer Res. 2026;46:4453-4460.
     PubMed    
     Abstract available
     
     

105. LISTER-WHELAN R, Senior E, Kendall J, Oughton JB, et al
     INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
     BJU Int. 2026 Jul 27. doi: 10.1111/bju.70387.
     PubMed    
     Abstract available
     
     

106. ZHANG L, Liu Z, Ding Y, Sun J, et al
     Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.
     Br J Cancer. 2026;135:559-567.
     PubMed    
     Abstract available
     
     

107. WALKER CH, Jabalameli N, Rais-Bahrami S
     Radiomic phenotypes in nonmuscle-invasive bladder cancer: A precision biomarker guiding therapy.
     Cancer. 2026;132:e70563.
     PubMed    
     Abstract available
     
     

108. GALSKY MD, Necchi A
     Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.
     Eur Urol. 2026 Jul 27:S0302-2838(26)02271-2. doi: 10.1016/j.eururo.2026.
     PubMed    
     Abstract available
     
     

109. MATSUSHITA Y, Kita Y, Mukai S, Joraku A, et al
     Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.
     Int J Urol. 2026;33:e70584.
     PubMed    
     Abstract available
     
     

110. KIKUCHI E, Tokumaru J, Kawai D, Ide R, et al
     Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study.
     Int J Urol. 2026;33:e70565.
     PubMed    
     Abstract available
     
     

111. ZHANG B, Wang C, Yang S, Li X, et al
     A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer.
     Int Urol Nephrol. 2026 Jul 25. doi: 10.1007/s11255-026-05275.
     PubMed    
     Abstract available
     
     

112. GAO Y, Chen C, Sun R, Yao Y, et al
     LncRMRP drives bladder cancer invasion via a lactylation-driven positive feedback circuit.
     Oncogene. 2026 Jul 30. doi: 10.1038/s41388-026-03927.
     PubMed    
     Abstract available
     
     

113. ZHAN Y, Zhu C, Li Y, Wen C, et al
     Transcription factor EN1 governs a lipogenic USP18-ACLY axis to drive bladder cancer malignancy.
     Oncogene. 2026 Jul 28. doi: 10.1038/s41388-026-03910.
     PubMed    
     Abstract available
     
     

114. XIONG R, Wang M, Du J, Chai B, et al
     USP15-mediated deubiquitination of FIS1 impairs mitochondrial function and sensitizes bladder cancer cells to radiotherapy.
     Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03918.
     PubMed    
     Abstract available